Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation

Department of Cell Biology, University of Cincinnati, Cincinnati, OH 45267, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 03/2006; 103(7):2190-5. DOI: 10.1073/pnas.0506281103
Source: PubMed


Cyclin D1 is a multifaceted regulator of both transcription and cell-cycle progression that exists in two distinct isoforms, cyclin D1a and D1b. In the prostate, cyclin D1a acts through discrete mechanisms to negatively regulate androgen receptor (AR) activity and thus limit androgen-dependent proliferation. Accordingly, cyclin D1a is rarely overexpressed in prostatic adenocarcinoma and holds little prognostic value in this tumor type. However, a common polymorphism (A870) known to facilitate production of cyclin D1b is associated with increased prostate cancer risk. Here we show that cyclin D1b is expressed at high frequency in prostate cancer and is up-regulated in neoplastic disease. Furthermore, our data demonstrate that, although cyclin D1b retains AR association, it is selectively compromised for AR regulation. The altered ability of cyclin D1b to regulate the AR was observed by using both in vitro and in vivo assays and was associated with compromised regulation of AR-dependent proliferation. Consistent with previous reports, expression of cyclin D1a inhibited cell-cycle progression in AR-dependent prostate cancer cells. Strikingly, cyclin D1b significantly stimulated proliferation in this cell type. AR-negative prostate cancer cells were nonresponsive to cyclin D1 (a or b) expression, indicating that defects in AR corepressor function yield a growth advantage specifically in AR-dependent cells. In summary, these studies indicate that the altered AR regulatory capacity of cyclin D1b contributes to its association with increased prostate cancer risk and provide evidence of cyclin D1b-mediated transcriptional regulation.

Download full-text


Available from: Chris Haiman,
  • Source
    • "The respective protein isoforms display different intracellular localization: while D1a shuttles between the nucleus and the cytoplasm, D1b is constitutively nuclear [98]. Both transcript variants are expressed in normal tissues but D1b often appears upregulated in several forms of cancer, including breast cancer [99, 100]. The oncogenic properties of D1b isoform have been extensively described [98, 101]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is widely accepted that tumorigenesis is a multistep process characterized by the sequential accumulation of genetic alterations. However, the molecular basis of genomic instability in cancer is still partially understood. The observation that hereditary cancers are often characterized by mutations in DNA repair and checkpoint genes suggests that accumulation of DNA damage is a major contributor to the oncogenic transformation. It is therefore of great interest to identify all the cellular pathways that contribute to the response to DNA damage. Recently, RNA processing has emerged as a novel pathway that may contribute to the maintenance of genome stability. In this review, we illustrate several different mechanisms through which pre-mRNA splicing and genomic stability can influence each other. We specifically focus on the role of splicing factors in the DNA damage response and describe how, in turn, activation of the DDR can influence the activity of splicing factors.
    International Journal of Cell Biology 09/2013; 2013(9):153634. DOI:10.1155/2013/153634
  • Source
    • "SNPs in the cyclin D1 proto-oncogene predispose for aberrant splicing and cyclin D1b intronic splice variant production, an instance where aberrant splicing leads to enhanced oncogenic potential rather than inactivation of tumor suppressor function [29] [128] [129] [130]. Similarly, polymorphisms in the HAS1 gene appear to predispose splicing events towards aberrant intronic splicing of cancerpromoting HAS1 variants, a conclusion supported by bioinformatic predictions and analysis of in vitro splicing [100] [127]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Current evidence suggests a significant role of aberrant splicing in the development and maintenance of malignancy. This multistep, tightly regulated epigenetic process leads to the production of abnormal proteins with abnormal functions contributing to underlying mechanisms of malignant transformation. Splicing patterns in malignant cells can be altered not only by the mutations detected on the aberrantly spliced gene, but also by the mutations detected on the genes encoding splicing factors. For example, aberrant pre-mRNA splicing, leading to intracellular or extracellular HA synthesis by HASs, contributes to the initiation and progression of various types of cancer. The influence of intracellular HA appears to be particularly significant and is promoted by aberrant splicing. In this review we report a model describing oncogenic potential of aberrant splicing, with a focus on HAS1 and intracellular HA. We We We also suggest that the influence of splicing mutations on malignant disease is likely multifactorial. For the triple axis of HA, HAS1 and RHAMM, mutations in HAS1 provide an indicator that these aberrations contribute to the events that lead to malignancy through increased risk and predisposition. Here, we also summarize the impact of splicing abnormalities on cancer and the possible oncogenic impact of aberrantly spliced HAS1. In conclusion, we emphasize that specific gene splice variants and the splicing process itself offer potential targets for novel drug treatment strategies.
    Current cancer drug targets 03/2013; 13(4). DOI:10.2174/1568009611313040001 · 3.52 Impact Factor
  • Source
    • "In line with its crucial role in the DNA damage response, several changes in AS of specific transcripts have been observed in cancer cells treated with cisplatin or etoposide. Remarkably, some of these transcripts encode for proteins regulating apoptosis, such as Caspase 2 (11) and Bcl-2 related genes (3), cell motility, like CD44 (12) and cell proliferation, like the p53 negative modulators MDM2 and MDM4 (13) or cyclin D1b, a splicing variant aberrantly expressed in prostate and breast cancer cells that confers resistance to therapies (14,15). Thus, it is likely that regulation of these AS events represents a novel mechanism by which cancer cells gain drug resistance and survive to chemotherapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: DNA-damaging agents cause a multifaceted cellular stress response. Cells set in motion either repair mechanisms or programmed cell death pathways, depending on the extent of the damage and on their ability to withstand it. The RNA-binding protein (RBP) Sam68, which is up-regulated in prostate carcinoma, promotes prostate cancer cell survival to genotoxic stress. Herein, we have investigated the function of Sam68 in this cellular response. Mitoxantrone (MTX), a topoisomerase II inhibitor, induced relocalization of Sam68 from the nucleoplasm to nuclear granules, together with several other RBPs involved in alternative splicing, such as TIA-1, hnRNP A1 and the SR proteins SC35 and ASF/SF2. Sam68 accumulation in nuclear stress granules was independent of signal transduction pathways activated by DNA damage. Using BrU labelling and immunofluorescence, we demonstrate that MTX-induced nuclear stress granules are transcriptionally active foci where Sam68 and the phosphorylated form of RNA polymerase II accumulate. Finally, we show that MTX-induced relocalization of Sam68 correlates with changes in alternative splicing of its mRNA target CD44, and that MTX-induced CD44 splicing depends on Sam68 expression. These results strongly suggest that Sam68 is part of a RNA-mediated stress response of the cell that modulates alternative splicing in response to DNA damage.
    Nucleic Acids Research 05/2010; 38(9):3005-18. DOI:10.1093/nar/gkq004 · 9.11 Impact Factor
Show more